{"id":"W2896458230","doi":"10.1016/s1470-2045(18)30618-1","title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"ca_institutions":"Foothills Medical Centre; University of Alberta","funders":"National Health and Medical Research Council; AstraZeneca Australia; Siemens; National Health Research Institutes; Engineering and Physical Sciences Research Council; National Institute for Health and Care Research; F. Hoffmann-La Roche","keywords":"Obinutuzumab; Medicine; Follicular lymphoma; Vincristine; Bendamustine; Rituximab; Internal medicine; Prednisone; Clinical endpoint; CHOP; Oncology; Cyclophosphamide; Surgery; Lymphoma; Gastroenterology; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001482565,0.0001643166,0.001372138,0.000202495,0.00004830616,0.000003424971,0.0001328865,0.0001085969,0.0003129619],"category_scores_gemma":[0.0004193037,0.000102592,0.0005256138,0.0003849735,0.0003331264,0.00002890327,0.00002578416,0.00004563317,0.000002397502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001672723,"about_ca_system_score_gemma":0.0004581721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009700675,"about_ca_topic_score_gemma":0.00007385877,"domain_scores_codex":[0.9983406,0.0003839681,0.0006358206,0.0002285082,0.0001840963,0.0002270084],"domain_scores_gemma":[0.9970863,0.001594848,0.0004853864,0.0005311077,0.0002546739,0.00004772194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9515629,0.003855651,0.002308496,0.0001076194,0.005074466,0.00003238957,0.001166509,0.000009725997,0.01048189,0.00009494338,0.000341977,0.02496338],"study_design_scores_gemma":[0.8270851,0.02486115,0.05133094,0.0001030891,0.00949965,0.00006775875,0.0001095387,0.001111078,0.07159489,0.000207243,0.01388809,0.0001415195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940763,0.0007245684,0.0002536629,0.002206378,0.0002468599,0.002170789,0.0001608887,0.0000143345,0.0001461863],"genre_scores_gemma":[0.9967119,0.0002705368,0.001350682,0.000293317,0.0004788838,0.0007365787,0.00007677887,0.00001731189,0.00006404335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1244779,"threshold_uncertainty_score":0.4183579,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03272674167592464,"score_gpt":0.3595032829152931,"score_spread":0.3267765412393684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}